0000000000003830
AUTHOR
Pauline Legris
showing 7 related works from this author
Nésidioblastose traitée par pasiréotide LAR : à propos d’un cas
2021
Resume Une patiente de 56 ans, diabetique de type 2, presentait des episodes d’hypoglycemies, qui ont persiste apres arret du traitement antidiabetique. Une epreuve de jeune authentifie une hypoglycemie organique, a 0,34 g/L, insulinemie a 6 mUI/L, peptide C a 1,9 ng/mL (normes : 0,5–3,0 ng/mL) et proinsuline a 3,72, puis 4,5 pmol/L (normes : 1,28–3,84 pmol/L). Aucune lesion n’est retrouvee au scanner ou a l’echo-endoscopie. La scintigraphie a la somatostatine est negative. Ces elements font ainsi porter le diagnostic de nesidioblastose. Des traitements par diazoxide et octreotide sont successivement mis en place, sans succes. Sous pasireotide LAR, les hypoglycemies disparaissent, avec meme…
Diabetes is not associated with COVID-19-related mortality in older institutionalized people
2021
Diabetes & Metabolism - Sous presse. Manuscrit accepte. Disponible en ligne depuis le mercredi 27 janvier 2021
Inhibiteurs PCSK9 en pratique clinique : données et interrogations
2020
Resume Les inhibiteurs de la « proprotein convertase subtilisin/kexin type 9 » (PCSK9) sont de nouveaux traitements de l’hypercholesterolemie. Ils induisent une diminution marquee du taux de LDL-cholesterol plasmatique de 50 a 60 %. Parallelement, ils reduisent significativement le risque d’evenements cardiovasculaires, comme cela a ete demontre dans plusieurs etudes prospectives. Par ailleurs, les inhibiteurs PCSK9 diminuent le taux plasmatique de lipoproteine (a) [Lp(a)] d’environ 25 %. Il semble que cette reduction du taux de Lp(a) participe au benefice cardiovasculaire, note avec les inhibiteurs PCSK9, en particulier chez les patients ayant des valeurs de base de Lp(a) augmentees. Les m…
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
2021
Introduction Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypo…
Fewer Type A personality traits in type 2 diabetes patients with diabetic foot ulcer.
2021
Abstract Aim Type A personality—characterized by time urgency, strong drive, and a need for achievement and competitiveness—has been shown to be associated with reduced mortality in patients with diabetes. However, it is not known whether a Type A personality might protect against diabetic foot ulcer (DFU). This prompted our present analysis of the association between Type A personality and DFU. Methods The Bortner Scale questionnaire was used to assess Type A personality in 386 patients with type 2 diabetes (T2D), including 104 patients also presenting with, and 282 presenting without, DFU. Additional questionnaires were used to assess perceived stress and depression. Results Type A Bortne…
Effets de la corticothérapie systémique sur le métabolisme des HDL
2020
Resume La prise exogene de glucocorticoides (GC) est responsable de nombreux effets secondaires, notamment metaboliques. Les effets sur le metabolisme lipidique ne se limitent pas aux triglycerides, mais concernent egalement les HDL. Meme si les donnees disponibles sont peu nombreuses, elles montrent que les GC entrainent une augmentation des taux plasmatiques de HDL-cholesterol et de la taille des particules HDL, independante de l’effet anti-inflammatoire des GC. Les mecanismes sous-jacents a ces augmentations restent actuellement meconnus. Alors que les patients traites par GC presentent une augmentation de la morbidite cardiovasculaire et que l’alteration de la fonctionnalite des HDL est…
Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients
2021
Abstract Obesity is increasing in patients with type 2 diabetes. A possible reduced association between fructosamine and glycated hemoglobin (HbA1c) in obese individuals has been previously discussed, but this has never been specifically evaluated in type 2 diabetes, and the potential influence of body fat mass and fat distribution has never been studied. We studied 112 type 2 diabetes patients with assessment of fat mass, liver fat and fat distribution. Patients with body mass index (BMI) above the median (34.9 kg/m2), versus BMI below the median, had a correlation coefficient between fructosamine and HbA1c significantly reduced (r = 0.358 vs r = 0.765). In the whole population, fructosami…